Home›Clinical trials›Florida

GLP-1 clinical trials in Florida: 40 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

40 GLP-1 clinical trials are recruiting at 224 sites in 64 cities across Florida. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Florida

  1. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    5 sites in Florida
    • NeoClinical Research, Hialeah. 305-456-9062
    • Encore Medical Research, Hollywood. 954-400-1725
    • Skin Care Research, Hollywood. 954-674-3535
    • MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research, Tampa. 813-948-7550
    • TruDerm & TruSpa, Wellington

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  2. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    5 sites in Florida
    • Vida Clinical Research, Kissimmee
    • Life Clinical Trials, Margate
    • CZ Rheumatology, Miami Beach
    • Vitalia Medical Research, Palm Beach Gardens. 5615591110
    • International Center for Research, Tampa

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  3. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Florida

    • Kendall South Medical Center, Inc, Miami. 305-388-1118
    • South Florida Research Solutions, LLC, Pembroke Pines. 954-986-3067

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  1. The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality

    Phase 4. The Cleveland Clinic plans to enroll 132 participants.

    A study listed on ClinicalTrials.gov.

    2 sites in Florida

    NCT07127354 on ClinicalTrials.gov. See whether you qualify.

  2. Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

    Phase 4. University of Miami plans to enroll 24 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18+, have Crohn's disease, BMI 27+.

    1 site in Florida

    NCT06774079 on ClinicalTrials.gov. See whether you qualify.

  3. The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

    Phase 4. Mayo Clinic plans to enroll 40 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help women going through menopause lose weight.

    Who can join. Adults 46 to 60, women only, have obesity, BMI 27+.

    1 site in Florida

    NCT07218445 on ClinicalTrials.gov. See whether you qualify.

  4. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    37 sites in Florida

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  5. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    31 sites in Florida

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  6. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    23 sites in Florida
    • K2 Medical Research WINTER GARDEN, Clermont. 407-426-9299
    • K2 Medical Research - Daytona Beach, Daytona Beach
    • Care Access - Delray Beach, Delray Beach. 401-773-7855
    • AMR Clinical, Doral
    • Southwest General Healthcare Center, Fort Myers. 239-931-3368
    • University of Florida College of Medicine, Gainesville. 352-273-8662
    • Encore Medical Research, Hollywood. 954-400-1725
    • Nature Coast Clinical Research - Inverness, Inverness. 352-341-2100
    • Encore Borland-Groover Clinical Research, Jacksonville. 904-680-0871
    • Health Awareness, Jupiter
    • K2 MEDICAL Research THE VILLAGES, Lady Lake. 352-500-5252
    • Florida Research Institute, Lakewood Rch. 941-727-7772
    • Tampa Bay Medical Research - Largo, Largo. 727-724-3316
    • Evolution Clinical Trials, Miami. 786-706-1216
    • Floridian Clinical Research, LLC, Miami Lakes. 305-330-9977
    • GI PROS Research, Naples. 239-571-0899
    • Charter Research - Orlando, Orlando
    • Headlands Research Orlando, Orlando. 407-705-3471
    • Progressive Medical Research, Port Orange. 386-304-7070
    • Covenant Metabolic Specialists - Riverview, Riverview. 941-894-2014
    • Care Access - St. Petersburg, St. Petersburg. 877-791-0656
    • Care Access - Tamarac, Tamarac. 877-791-0656
    • Covenant Metabolic Specialists, LLC, University Park. 941-894-2014

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  7. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    15 sites in Florida

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

The other 30 studies recruiting in Florida

  1. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    10 sites in Florida
    • TBMR & Alcanza, Clearwater
    • Northeast Research Institute, Fleming Island
    • Northeast Research Institute, Jacksonville
    • Westside Center For Clinical Research, Jacksonville
    • Bioclinical Research Alliance, Miami
    • New Horizon Research Center, Miami
    • South Broward Research LLC, Miramar
    • West Orange Endocrinology, Ocoee
    • Oviedo Medical Research, LLC, Oviedo
    • Clinical Trial Services Corp, Pembroke Pines

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  2. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Amgen plans to enroll 300 participants.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    9 sites in Florida
    • University of Florida Department of Medicine, Gainesville
    • Aga Clinical Trials, Hialeah
    • South Florida Clinical Research, Margate
    • New Horizon Research Center, Miami
    • Research Institute of South Florida, Miami
    • Clinical Neuroscience Solutions, Orlando
    • Florida Institute for Clinical Research, Orlando
    • Progressive Medical Research, Port Orange
    • Charter Research - The Villages, The Villages

    NCT07575399 on ClinicalTrials.gov. See whether you qualify.

  3. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    6 sites in Florida
    • Gastro Health Research - Miami, Miami
    • Research Associates of South Florida - Miami - Southwest 8th Street, Miami
    • Digestive and Liver Center of Florida, Orlando. 407-384-7388
    • Orlando Health, Orlando
    • Gastro Health Research - Pensacola, Pensacola
    • Precision Clinical Research, Sunrise

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  4. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    6 sites in Florida
    • Gastro Health Research - Miami, Miami
    • Research Associates of South Florida - Miami - Southwest 8th Street, Miami
    • Digestive and Liver Center of Florida, Orlando. 407-384-7388
    • Orlando Health, Orlando
    • Gastro Health Research - Pensacola, Pensacola
    • Precision Clinical Research, Sunrise

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  5. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    5 sites in Florida
    • Research Site, Crystal River
    • Research Site, Hollywood
    • Research Site, Jacksonville
    • Research Site, Leesburg
    • Research Site, Orlando

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  6. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    4 sites in Florida

    • William A. Shands Hospital at the University of Florida, Gainesville
    • Florida Hospital- Center for Pediatric Research, Orlando
    • Nemours Children's Health, Orlando
    • All Childrens Hospital, St. Petersburg

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  7. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Eli Lilly and Company plans to enroll 1,000 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    4 sites in Florida

    • AMR Clinical, Fort Myers. 239-936-4421
    • Altus Research, Lake Worth. 561-641-0404
    • New Age Medical Research Corporation, Miami. 305-596-9901
    • Emerald Coast OBGYN Clinical Research, Panama City

    NCT07202884 on ClinicalTrials.gov. See whether you qualify.

  8. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    4 sites in Florida

    • Lakeview Institute of Clinical Research, Leesburg. 352-782-0606
    • Floridian Clinical Research, LLC, Miami Lakes. 305-330-9977
    • Inpatient Research Clinic, Miami Lakes. 786-502-4303
    • St Johns Center for Clinical Research, Saint Augustine. 904-209-0043

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

  9. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 460 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    3 sites in Florida

    • Encore Medical Research LLC, Hollywood
    • Jacksonville Ctr for Clin Res, Jacksonville
    • Encore Medical Research of Weston, Weston

    NCT07253285 on ClinicalTrials.gov. See whether you qualify.

  10. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 450 participants.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    3 sites in Florida

    • ERG Holding Company, LLC / Evolution Research Group, LLC, Delray Beach
    • ERG Holding Company, LLC / Evolution Research Group, LLC, Fort Myers
    • Jedidiah Clinical Research, Tampa

    NCT07770841 on ClinicalTrials.gov. See whether you qualify.

  11. Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

    Phase 3. Altimmune, Inc plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Altimmune, pemvidutide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (also called MASH or NASH), BMI 23+.

    2 sites in Florida

    • Altimmune Clinical Study Site, Miami
    • Altimmune Clinical Study Site, Ocala

    NCT07795164 on ClinicalTrials.gov. See whether you qualify.

  12. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. VA Office of Research and Development plans to enroll 622 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Florida

    • Orlando VA Healthcare System, Orlando, FL, Orlando. 407-631-4011

    NCT07218354 on ClinicalTrials.gov. See whether you qualify.

  13. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Kailera plans to enroll 1,200 participants.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Florida

    • Kailera Clinical Site, Orange City

    NCT07284979 on ClinicalTrials.gov. See whether you qualify.

  14. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Vanda Pharmaceuticals plans to enroll 280 participants.

    A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    1 site in Florida

    NCT07446439 on ClinicalTrials.gov. See whether you qualify.

  15. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    6 sites in Florida
    • Northeast Research Institute (NERI), Fleming Island
    • New Horizon Research Center, Miami. 305-226-3933
    • Indago Research & Health Center, Inc, Miami Lakes. 305-825-6588
    • Suncoast Clinical Research, Inc., New Port Richey. 727-849-4131
    • Charter Research - Winter Park, Orlando. 407-337-3000
    • Charter Research - Lady Lake, The Villages. 352-441-2000

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  16. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 270 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    5 sites in Florida
    • Encore Medical Research LLC, Hollywood
    • Bioclinical Research Alliance, Miami
    • South Broward Research LLC, Miramar
    • West Orange Endocrinology, Ocoee
    • Encore Medical Research of Weston, Weston

    NCT07415954 on ClinicalTrials.gov. See whether you qualify.

  17. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Novo Nordisk A/S plans to enroll 465 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    4 sites in Florida

    • Northeast Research Institute, Fleming Island
    • Encore Medical Research LLC, Hollywood
    • Northeast Research Institute, Saint Augustine
    • Clinical Research of Cent FL, Winter Haven

    NCT06717698 on ClinicalTrials.gov. See whether you qualify.

  18. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Biomea Fusion Inc plans to enroll 60 participants.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    3 sites in Florida

    • Southwest General Healthcare Center, Fort Myers
    • Panax Clinical Research, Miami Lakes
    • Flourish Research Orlando, Winter Park

    NCT07502508 on ClinicalTrials.gov. See whether you qualify.

  19. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    3 sites in Florida

    • Encore Medical Research LLC, Hollywood
    • South Broward Research LLC, Miramar
    • West Orange Endocrinology, Ocoee

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  20. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 300 participants.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    3 sites in Florida

    • Encore Medical Research LLC, Hollywood
    • South Broward Research LLC, Miramar
    • Encore Medical Research of Weston, Weston

    NCT07668388 on ClinicalTrials.gov. See whether you qualify.

  21. Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

    Phase 2. Regeneron Pharmaceuticals plans to enroll 360 participants.

    A study testing whether a GLP-1 and GIP medicine from Regeneron Pharmaceuticals, olatorepatide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27+.

    3 sites in Florida

    • K2 Medical Research Maitland LLC, Main Office, Maitland
    • Charter Research LLC - The Villages, The Villages
    • Clinical Site Partners, LLC DBA Flourish Research, Winter Park

    NCT07685808 on ClinicalTrials.gov. See whether you qualify.

  22. Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Phase 2. T. John Winhusen, PhD plans to enroll 310 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder, BMI 23+.

    2 sites in Florida

    NCT06651177 on ClinicalTrials.gov. See whether you qualify.

  23. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Eli Lilly and Company plans to enroll 240 participants.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    2 sites in Florida

    NCT06897475 on ClinicalTrials.gov. See whether you qualify.

  24. A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type

    Phase 2. Antag Therapeutics plans to enroll 150 participants.

    A study testing whether an investigational medicine from Antag Therapeutics, AT673, can help people who are overweight lower blood sugar and lose weight.

    Who can join. Adults 18+, have type 2 diabetes, BMI 27+.

    2 sites in Florida

    NCT07724340 on ClinicalTrials.gov. See whether you qualify.

  25. Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

    Phase 2. AdventHealth Translational Research Institute plans to enroll 47 participants.

    A study testing whether a GLP-1 medicine, dulaglutide, can help people with type 1 diabetes lower blood sugar.

    Who can join. Adults 18 to 40, have type 1 diabetes, BMI 19+.

    1 site in Florida

    • AdventHealth Translational Research Institute, Orlando

    NCT05478707 on ClinicalTrials.gov. See whether you qualify.

  26. A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel

    Phase 2. University of Florida plans to enroll 20 participants.

    A study of a GLP-1 medicine, orforglipron, in people with endometrial cancer.

    Who can join. Adults 18+, women only, have endometrial cancer, BMI 30+.

    1 site in Florida

    NCT07107334 on ClinicalTrials.gov. See whether you qualify.

  27. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Novo Nordisk A/S plans to enroll 114 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    4 sites in Florida

    • Northeast Research Institute, Fleming Island
    • Jacksonville Ctr For Clin Res, Jacksonville
    • Center for Diab,Obes & Metab, Pembroke Pines
    • Encore Medical Research of Weston, Weston

    NCT07607587 on ClinicalTrials.gov. See whether you qualify.

  28. A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

    Phase 1. Novo Nordisk A/S plans to enroll 80 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people lose weight.

    Who can join. Adults 18 to 65, have obesity, BMI 30+.

    1 site in Florida

    • Advent Health-Res Inst, Orlando

    NCT07184086 on ClinicalTrials.gov. See whether you qualify.

  29. Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

    Abbott Diabetes Care plans to enroll 800 participants.

    A study in people with diabetes.

    Who can join. Adults 18+, have diabetes.

    2 sites in Florida

    • East Coast Institute for Research, LLC, Jacksonville. 904-854-1354
    • Excellence Medical and Research, Miami Gardens. 786-320-5229

    NCT06668935 on ClinicalTrials.gov. See whether you qualify.

  30. Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic

    Nemours Children's Clinic plans to enroll 20 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people manage PCOS.

    Who can join. Children and teens 12 to 18, women only, have polycystic ovary syndrome (PCOS).

    1 site in Florida

    NCT07169136 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.